TheraRadar
Clinical-Stage Companies / Allodynic

Allodynic

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 1/31/2025

7
Total Trials
2
Phase 3
7
Phase 2
0
Recruiting
86
Score

Pipeline by Phase

Phase 3
2
Phase 2
7
Phase 1

Therapeutic Focus

Migraine With or Without Aura Migraine Chronic Low Back Pain Lumbar Radiculopathy Migraine With and Without Aura

Clinical Trials (7)

NCT05685225 Phase 2 WITHDRAWN

Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial

Started: 1/31/2025

NCT03194555 Phase 2 COMPLETED

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

Started: 8/25/2017

NCT06245902 Phase 2 COMPLETED

An Acute Migraine Factorial Study

Started: 2/18/2017

NCT03201393 Phase 2 COMPLETED

Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)

Started: 8/15/2017

NCT03061734 Phase 2 COMPLETED

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

Started: 2/18/2017

NCT03185143 Phase 2 COMPLETED

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

Started: 6/27/2017

NCT01920087 Phase 2 WITHDRAWN

Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain

Started: 3/1/2014

Drug Candidates

Stage 1: Naltrexone/Acetaminophen Stage 1: Naltrexone Stage 1: Acetaminophen Stage1: Placebo Stage 2: Naltrxone/Acetaminophen high dose Stage 2: Naltrexone/Acetaminophen medium dose Stage 2: Naltrxone/Acetaminophen low dose Stage 2: Placebo Low-Dose Naltrexone and Acetaminophen Combination Placebo
Activity Status: Slowing
Last Trial Started: 1/31/2025
Last Trial Ended: 7/28/2018
Trials (12 months): 0
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.